Last $165.47 USD
Change Today -4.70 / -2.76%
Volume 1.9M
AMGN On Other Exchanges
Symbol
Exchange
Hong Kong
Mexico
Sao Paulo
Frankfurt
As of 1:21 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Open
$168.31
Previous Close
$170.17
Day High
$169.04
Day Low
$163.91
52 Week High
12/8/14 - $173.14
52 Week Low
04/28/14 - $108.20
Market Cap
126.1B
Average Volume 10 Days
4.1M
EPS TTM
$6.75
Shares Outstanding
760.7M
EX-Date
02/10/15
P/E TM
24.6x
Dividend
$3.16
Dividend Yield
1.47%
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company’s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company’s products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

20,000 Employees
Last Reported Date: 02/24/14
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $896.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $845.9K
Compensation as of Fiscal Year 2013.

amgen inc (AMGN) Key Developments

Amgen Declares Dividend for the First Quarter of 2015, Payable on March 6, 2015

Amgen announced that its board of directors declared a $0.79 per share dividend for the first quarter of 2015. The dividend will be paid on March 6, 2015, to all stockholders of record as of the close of business on February 12, 2015. This represents a 30% increase from that paid in each of the previous four quarters.

Amgen Announces Results from Acute Lymphoblastic Leukemia Study

Amgen Inc. announced new data from the Phase II BLAST study which evaluated the bispecific T cell engager, or BiTE, immunotherapy BLINCYTO in patients with minimal residual disease, or MRD, positive B-cell precursor acute lymphoblastic leukemia, or ALL. In the study, 78% of patients who received BLINCYTO experienced a complete MRD response (95% CI: 69-85%), a measure of eradication of residual disease at the molecular level, after one treatment cycle. Nearly all complete responses (98%) occurred within the first treatment cycle. In addition to the majority (78%) of patients achieving a compete MRD response within one cycle of treatment, 80% achieved a complete MRD response across all cycles. Responses occurred in all subgroups including older patients and patients with high MRD level; no predictive factor for MRD response was identified. In the study, adverse events (AEs) of all grades occurring in 20% or more patients included pyrexia (90%), tremor (29%), chills (26%), fatigue (24%), nausea (22%), vomiting (22%) and diarrhea (20%). Grade greater than or equal to 3 AEs occurring in 5% or more patients included neutropenia (16%), pyrexia (7%) and tremor (5%). Two fatal AEs occurred on treatment: subdural hemorrhage and pneumonitis in conjunction with influenza (the latter was deemed treatment-related). Treatment interruptions due to AEs occurred in 31% of patients. The BLAST study is the large prospective trial in patients with MRD-positive ALL. It is an open-label, multicenter, confirmatory single-arm, Phase II study evaluating the efficacy, safety and tolerability of BLINCYTO in adult patients (greater than or equal to 18 years) with MRD positive B-cell precursor.

Amgen Presents Data from Pivotal Phase 2 Study of BLINCYTO™ (Blinatumomab) Immunotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Amgen announced that new data from a pivotal Phase 2 study evaluating BLINCYTO™ (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. In one analysis from the '211 study, 40% of patients treated with BLINCYTO who achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh) were enabled to proceed to allogeneic hematopoietic stem cell transplant (HSCT). Additionally, a secondary analysis from the study found that 82% of patients who had a CR or CRh also had a minimal residual disease (MRD) response, a measure used to predict disease recurrence in patients with ALL. In the study, the most frequent grade >3 adverse events (AEs) occurring in >5% of patients were febrile neutropenia (25%), neutropenia (16%), anemia (14%), pneumonia (9%), thrombocytopenia (8%), hyperglycemia (8%), leukopenia (8%), alanine aminotransferase increased (7%), hypokalemia (7%), pyrexia (7%), sepsis (6%), hypophosphatemia (5%). Grade > 3 neurologic events occurred in 13% of patients, and grade > 3 cytokine release syndrome occurred in 2% of patients. ASH Abstract 965: Allogeneic Hematopoietic Stem Cell Transplantation Following anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia In one analysis of the '211 study, 40% of patients treated with BLINCYTO who achieved a CR or CRh were enabled to proceed to HSCT, including both patients who had received prior HSCT and patients who had not received prior HSCT. Additionally, the analysis found that responses to BLINCYTO were similar between patients who had received prior HSCT and patients who had not received HSCT (45% versus 42%, respectively). ASH Abstract 3704: An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Receiving Treatment with the BiTE® antibody construct Blinatumomab. A secondary analysis of the study demonstrated that, among patients receiving BLINCYTO who had a CR or CRh and had evaluable MRD data (n=73), 82% had an MRD response, with 70% of those patients achieving a complete MRD response. The single arm, open-label, multicenter Phase 2 trial evaluated the safety and efficacy of BLINCYTO in adult patients with Philadelphia chromosome-negative (Ph-) B-precursor ALL who had relapsed or were refractory following treatment with standard front-line chemotherapy or allogeneic stem cell transplant. Patients received up to five four-week cycles of intravenous BLINCYTO treatment. The primary endpoint of the study was the rate of CR/CRh within the first two treatment cycles. Secondary endpoints include duration of CR and CRh, relapse-free survival, overall survival, HSCT realization rate, 100-day mortality rate and adverse events.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $165.65 USD -4.52

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $167.04 USD +1.56
AbbVie Inc $67.39 USD -0.32
Eli Lilly & Co $71.21 USD -1.19
Gilead Sciences Inc $95.30 USD -13.15
Novo Nordisk A/S kr267.20 DKK +1.20
View Industry Companies
 

Industry Analysis

AMGN

Industry Average

Valuation AMGN Industry Range
Price/Earnings 26.8x
Price/Sales 6.6x
Price/Book 5.1x
Price/Cash Flow 26.5x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit www.amgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.